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Introduction
HIV, hepatitis C (HCV), and human T-cell lymphotro-
pic virus I (HTLV-1) are associated with high global
burdens of disease, notably in resource-poor locales.
They share similar routes of transmission and cause
chronic infections with associated morbidity. We per-
formed a cross-sectional study to assess the impact of
HTLV-1 infection on clinical outcomes in HIV/HCV
co-infected patients.
Methods
We enrolled 102 (72.3%) with HIV/HCV co-infection
(Group 1) and 39 (27.7%) triply infected with HIV,
HCV, and HTLV-1 (Group 2). We reviewed medical
records of two groups of patients followed in two outpa-
tients services in Salvador, Brazil. We collected and
compared demographic, behavioral-related information,
immunological, virological and histological parameters
for HIV-1 and HCV infection.
Results
Demographics, virological and immunological character-
istics were similar in the two groups; a higher propor-
tion of triply infected patients (Group 2) reported any
history of injection drug use (IDU) compared to dually
infected (Group 1) patients (75% vs. 45.8%; p =0.003).
No differences were seen between groups in HIV clini-
cal outcomes (CD4 count and viral load). Alanine ami-
notransferase levels were significantly higher in HIV/
HCV co-infected patients (p =0.045). Liver fibrosis
damage based on Metavir scores were similar between
groups (0.97) but were worse with lower CD4 cell count
(under 200cells/mm3) (p = 0.01).
Conclusions
HIV/HTLV-1 and HIV/HCV coinfections may worsen
clinical related outcomes, but virological and immunolo-
gical outcomes were similar in both groups. Hepatic
measures were worse in patients with more severe
immunosuppression.
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